According to clinical guidelines, NS3/4A protease inhibitors, including paritaprevir, grazoprevir, glecaprevir, and voxilaprevir are contraindicated in patients with Child–Pugh class B or C decompensated cirrhosis due to significant elevation in protease inhibitor concentrations and the associated risk of toxicity [12, 22]. This evidence concerns the gene KRAS and Cirrhosis.